This platelet-specific dysregulation contrasts with KTN1’s pan-cancer oncogenic role: Tumor tissue analyses (UALCAN) demonstrate consistent KTN1 upregulation across malignancies, where high expression correlates with poor survival in LAC, HCC, and TNBC through driving metastasis, NF-κB-mediated CXCL8 activation, and immune evasion (61). Here, KTN1 is linked to cancer.